Drugs / Fludarine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT05318963 Background | Mar 2022 → Jan 2025 | B-cell non-Hodgkin lymphoma | Institute of Hematology & Blood Diseases Hospital, China | Terminated | No outcome recorded |
| — | NCT04447547 Background | Jun 2020 → Aug 2022 | non-Hodgkin lymphoma | Hebei Senlang Biotechnology Inc., Ltd. | Unknown | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fludarine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04447547 ↗ |